Inovio Pharmaceuticals (INO) Publishes Revenue Results, Misses Awaitations By $0.03 EPS

Inovio Pharmaceuticals (INO) Publishes  Revenue Results, Misses Awaitations By $0.03 EPS

NASDAQ INO opened at $3.65 on Thursday. The company has a market capitalization of $348.03 million, a price-to-earnings ratio of -3.48 and a beta of 1.72. Inovio Pharmaceuticals has a fifty-two week low of $3.02 and a fifty-two week high of $6.30.

Inovio Pharmaceuticals (NASDAQ:INO) issued its earnings results on Tuesday. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.31) by ($0.03), RTT News reports. Inovio Pharmaceuticals had a negative return on equity of 88.61% and a negative net margin of 318.11%. The firm had revenue of $2.50 million for the quarter, compared to analysts’ expectations of $2.69 million. During the same quarter in the previous year, the firm posted ($0.23) EPS.

A number of brokerages have recently issued reports on INO. HC Wainwright set a $13.00 target price on Inovio Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, November 27th. Maxim Group set a $8.00 price target on Inovio Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, November 26th. BidaskClub upgraded Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, November 23rd. ValuEngine upgraded Inovio Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Wednesday, November 21st. Finally, Zacks Investment Research upgraded Inovio Pharmaceuticals from a “hold” rating to a “buy” rating and set a $5.25 price target for the company in a report on Thursday, January 24th. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $9.65.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. American Century Companies Inc. acquired a new position in shares of Inovio Pharmaceuticals in the 4th quarter valued at approximately $495,000. Geode Capital Management LLC raised its position in shares of Inovio Pharmaceuticals by 14.2% in the 4th quarter. Geode Capital Management LLC now owns 1,004,095 shares of the biopharmaceutical company’s stock valued at $4,016,000 after purchasing an additional 124,966 shares in the last quarter. Dimensional Fund Advisors LP raised its position in shares of Inovio Pharmaceuticals by 41.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 737,962 shares of the biopharmaceutical company’s stock valued at $2,952,000 after purchasing an additional 217,536 shares in the last quarter. Amalgamated Bank acquired a new position in shares of Inovio Pharmaceuticals in the 4th quarter valued at approximately $50,000. Finally, Public Employees Retirement System of Ohio raised its position in shares of Inovio Pharmaceuticals by 14.9% in the 4th quarter. Public Employees Retirement System of Ohio now owns 224,765 shares of the biopharmaceutical company’s stock valued at $899,000 after purchasing an additional 29,136 shares in the last quarter. Hedge funds and other institutional investors own 37.31% of the company’s stock.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza.

Further Reading: What is the Stochastic Momentum Index (SMI)?

Related posts

Leave a Comment